Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients (BRIGHT 1012)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02367456
Recruitment Status : Active, not recruiting
First Posted : February 20, 2015
Last Update Posted : November 17, 2020
Sponsor:
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date  ICMJE February 13, 2015
First Posted Date  ICMJE February 20, 2015
Last Update Posted Date November 17, 2020
Actual Study Start Date  ICMJE April 28, 2015
Actual Primary Completion Date January 29, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 9, 2019)
  • Complete remission (CR) rate for MDS [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    CR rate - percentage of patients achieving CR as defined by modified IWG criteria (2006) for MDS (Expansion cohort)
  • Complete remission (CR) rate for AML [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    CR rate - percentage of patients achieving CR as defined by ELN (2017) for AML (Expansion cohort)
  • Adverse events (Safety lead-in phase) [ Time Frame: Screening through 28 days following last dose of study drug ]
    Adverse events as characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03), timing, seriousness and relationship to study therapy, and laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v.4.03) and timing (Safety lead-in phase)
Original Primary Outcome Measures  ICMJE
 (submitted: February 13, 2015)
RR (hematology) [ Time Frame: All cycles up until 30 months from randomization ]
Response rate (percentage of patients achieving CR + PR) as defined by modified IWG criteria (2006) (Phase 2)
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 9, 2019)
  • Response Rate [ Time Frame: All cycles until progression, a median of 1 year ]
    Response rate - Percentage of participants achieving complete remission + partial remission as defined by modified IWG criteria (2006) (Safety lead-in phase)
  • Hematologic Improvement [ Time Frame: All cycles until progression, a median of 1 year ]
    Hematologic Improvement, as defined by modified IWG criteria (2006) (Safety lead-in phase)
  • Marrow Complete Response (mCR) [ Time Frame: All cycles until progression, a median of 1 year ]
    Marrow Complete Response, as defined by modified IWG criteria (2006) (Safety lead-in phase)
  • Cytogenetic Response [ Time Frame: All cycles until progression, a median of 1 year ]
    Cytogenetic Response, as defined by modified IWG criteria (2006) (Safety lead-in phase)
  • Stable Disease [ Time Frame: All cycles until progression, a median of 1 year ]
    Stable Disease, as defined by modified IWG criteria (2006) (Safety lead-in phase)
  • AUC for Azacitidine [ Time Frame: First 2 weeks of treatment ]
    Area under the Concentration-Time Curve (ng*h/mL) (Safety lead-in phase)
  • Cmax for Azacitidine [ Time Frame: First 2 weeks of treatment ]
    Maximum Observed Plasma Concentration (ng/mL) (Safety lead-in phase)
  • Tmax for Azacitidine [ Time Frame: First 2 weeks of treatment ]
    Time to Reach Maximum Observed Plasma Concentration (hrs) (Safety lead-in phase)
  • AUC for PF-04449913 [ Time Frame: First 5 months of treatment ]
    Area under the Concentration-Time Curve (ng*h/mL) (Safety lead-in phase)
  • Cmax for PF-04449913 [ Time Frame: First 5 months of treatment ]
    Maximum Observed Plasma Concentration (ng/mL) (Safety lead-in phase)
  • Tmax for PF-04449913 [ Time Frame: First 5 months of treatment ]
    Time to Reach Maximum Observed Plasma Concentration (hrs) (Safety lead-in phase)
  • Ctrough for PF-04449913 [ Time Frame: First 1 month of treatment ]
    Minimum plasma concentration following daily dosing to steady state (ng/mL) (Expansion cohorts)
  • QTc interval [ Time Frame: All cycles through end of treatment, a median of 1 year ]
    QTc interval corrected using Fridericia's Formula (msec) (Safety lead-in phase and Expansion cohorts)
  • Overall Survival (OS) [ Time Frame: All cycles until death or 24 months from first visit of last patient ]
    Time from date of first study treatment to date of death due to any cause. Patients last known to be alive without date of death documented will be censored at the date of last contact. (Expansion cohorts)
  • Marrow complete remission (MDS Expansion cohort) [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    As defined by modified IWG criteria (2006) (MDS expansion cohort)
  • Partial remission (MDS Expansion cohort) [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    As defined by modified IWG criteria (2006) (MDS expansion cohort)
  • Stable disease (MDS Expansion cohort) [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    As defined by modified IWG criteria (2006) (MDS expansion cohort)
  • Partial or complete cytogenetic response (MDS Expansion cohort) [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    As defined by modified IWG criteria (2006) (MDS expansion cohort)
  • Hematologic improvement (MDS Expansion cohort) [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    As defined by modified IWG criteria (2006) (MDS expansion cohort)
  • Complete remission with incomplete hematologic recovery (AML Expansion cohort) [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    As defined by ELN criteria (2017) (AML expansion cohort)
  • Complete remission with partial hematologic recovery (AML Expansion cohort) [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    CRh is defined as CR but with absolute neutrophil count >500/uL, platelets >50,000/uL, and not qualifying for CR (AML Expansion cohort)
  • Morphologic leukemia free state (AML Expansion cohort) [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    As defined by ELN criteria (2017) (AML expansion cohort)
  • Partial remission (AML Expansion cohort) [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    As defined by ELN criteria (2017) (AML expansion cohort)
  • Stable disease (AML Expansion cohort) [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    As defined by ELN criteria (2017) (AML expansion cohort)
  • Duration of CR [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    Duration of CR defined as duration from date of first achieving CR to date of disease progression after CR, or death due to any cause, whichever occurs first (Expansion cohorts)
  • Time to CR [ Time Frame: All cycles until progression or 24 months from first visit of last patient ]
    Duration from date of first dose of study drug to date of CR (Expansion cohorts)
  • Adverse events (Expansion cohorts) [ Time Frame: Date of informed consent through 28 days following last dose of study drug ]
    Type, frequency, severity, timing, and relationship to study therapy of adverse events and laboratory abnormalities (graded by NCI CTCAE v.4.03) (Expansion cohorts)
Original Secondary Outcome Measures  ICMJE
 (submitted: February 13, 2015)
  • RR(Hematology) [ Time Frame: All Cycles up until 30 months from randomization ]
    Response Rate - (Percentage of Participants achieving CR + PR) as defined by modified IWG criteria (2006)(Phase 1)
  • Hematologic Improvement [ Time Frame: All cycles up until 30 months from randomization ]
    Hematologic Improvement, as defined by modified IWG (2006) (Phase 1).
  • Marrow Complete Response (mCR) [ Time Frame: All cycles up until 30 months from randomization ]
    Marrow Complete Response, as defined by modified IWG (2006) (Phase 1).
  • Cytogenetic Response [ Time Frame: All cycles up until 30 months from randomization ]
    Cytogenic Response as defined by modified IWG (2006) (Phase 1).
  • Transfusion Independence [ Time Frame: All cycles up until 30 months from randomization ]
    Proportion of patients becoming transfusion independent on study in patients who were transfusion dependent at the time of study entry (Phase 1).
  • Stable Disease [ Time Frame: All cycles up until 30 months from randomization ]
    Stable Disease as defined by modified IWG (2006) (Phase 1).
  • QTc interval [ Time Frame: Cycle 1 through Cycle 6 and End of Treatment up until 30 months from randomization ]
    QTc interval corrected using Fridericia's Formula (msec) (Phase 1)
  • AUC for PF-04449913 [ Time Frame: 0. .25, .5, 1, 2, 4, 6, and 24 hours post-dose ]
    Area under the Concentration-Time Curve (ng*h/mL) (Phase 1).
  • Cmax for PF-04449913 [ Time Frame: 0, .25, .5, 1, 2, 4, 6, and 24 hours post-dose ]
    Maximum Observed Plasma Concentration (ng/mL) (Phase 1).
  • Tmax for PF-04449913 [ Time Frame: 0, .25, .5, 1, 2, 4, 6, and 24 hours post-dose ]
    Time to Reach Maximum Observed Plasma Concentration (hrs) (Phase 1).
  • AUC for Azacitidine [ Time Frame: 0, .25, .5, 1, 2, and 6 hours post-dose ]
    Area under the Concentration-Time Curve (ng*h/mL) (Phase 1).
  • Cmax for Azacitidine [ Time Frame: 0, .25, .5, 1, 2, and 6 hours post-dose ]
    Maximum Observed Plasma Concentration (ng/mL) (Phase 1).
  • Tmax for Azacitidine [ Time Frame: 0, .25, .5, 1, 2 and 6 hours post-dose ]
    Time to Reach Maximum Observed Plasma Concentration (hrs) (Phase 1).
  • Duration of Hematologic Improvement (HI) [ Time Frame: All cycles until disease progression or up until 30 months from randomization ]
    Duration of HI defined as time from start of first documented HI to first documented disease progression or relapse after HI or death due to any cause, whichever occurs first (Phase 2).
  • Time to Best Response or any hematologic improvement [ Time Frame: All cycles up until 30 months from randomization ]
    Time from randomization to achieving best response CR, PR or any HI. (Phase 2 only).
  • Survival: Probability of Participant Survival [ Time Frame: 12, 18 and 24 months ]
    Probability of survival at 12, 18 and 24 months after randomization (Phase 2).
  • Hematologic Improvement [ Time Frame: All cycles up until 30 months from randomization ]
    Hematologic Improvement, as defined by modified IWG (2006) (Phase 2).
  • Transfusion independence [ Time Frame: All cycles up until 30 months from randomization ]
    Proportion of patients becoming transfusion independent on study in patients who were transfusion dependent at the time of study entry (Phase 2).
  • QTc interval [ Time Frame: Cycle 1 through Cycle 6 and End of Treatment up until 30 months from randomization ]
    QTc interval corrected using Fridericia's Formula (msec) (Phase 2)
  • Marrow Complete Response (mCR) [ Time Frame: All cycles up until 30 months from randomization ]
    Marrow Complete Response, as defined by modified IWG (2006) (Phase 2).
  • Cytogenic Response [ Time Frame: All cycles up until 30 months from randomization ]
    Cytogenic Response as defined by modified IWG (2006) (Phase 2).
  • Stable Disease [ Time Frame: All cycles up until 30 months from randomization ]
    Stable Disease as defined by modified IWG (2006) (Phase 2).
  • Duration of Response [ Time Frame: All cycles until progression or up until 30 months from randomization ]
    Duration of response (DR) defined as time from start of first documented disease response [Complete Response (CR) or Partial Response (PR)] to first documented disease progression or death due to any cause, whichever occurs first (Phase 2).
  • Time to First Response or any hematologic improvement [ Time Frame: All cycles up until 30 months from randomization ]
    Time from randomization to first achieving CR, PR or HI (Phase 2).
  • Time to reaching >30% bone marrow blasts [ Time Frame: All cycles up unitl 30 months from randomization ]
    From Randomization to first reaching >30% bone marrow blasts (Phase 2).
  • Ctrough [ Time Frame: Cycle 1 Day 15 and Cycle 2 Day 1 ]
    Minimum Observed Plasma Trough Concentration (ng/mL)(Phase 2).
  • Overal Survival (OS) [ Time Frame: Randomization till death up until 30 months from randomization ]
    Overall survival was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact (Phase 2).
  • Event Free Survival [ Time Frame: All Cycles up until 30 months from randomization ]
    Time from Randomization to first documentation of bone marrow blasts >30% or death for any reason whichever occurs first (Phase 2).
  • EQ-5D [ Time Frame: Baseline and Every Cycle up until 30 months from randomization ]
    Change From Baseline in Euro Quality of Life - Health State Profile Utility, Visual Analog Scale (VAS), and Dimension Health State EuroQol Score at Every Cycle (Phase 2).
  • EORTC-QLQ-C30 [ Time Frame: Baseline and Every Cycle up until 30 months from randomization ]
    European Organization of Research and the Treatment of Cancer- Quality of Life Core Questionnaire (Phase 2)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
Official Title  ICMJE AN OPEN-LABEL PHASE 1B STUDY OF PF-04449913 (GLASDEGIB) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA
Brief Summary This multi center open label Phase 1b study is designed to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of glasdegib (PF-04449913) when combined with azacitidine in patients with previously untreated Higher Risk Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). This clinical study includes two components: (a) a safety lead in cohort (LIC) and (b) an expansion phase with an AML cohort and an MDS cohort.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
Intervention  ICMJE
  • Drug: PF-04449913 (Glasdegib)
    Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
  • Drug: Azacitidine
    75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
Study Arms  ICMJE
  • Experimental: Arm A
    MDS patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
    Interventions:
    • Drug: PF-04449913 (Glasdegib)
    • Drug: Azacitidine
  • Experimental: Arm B
    AML patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
    Interventions:
    • Drug: PF-04449913 (Glasdegib)
    • Drug: Azacitidine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: June 9, 2019)
73
Original Estimated Enrollment  ICMJE
 (submitted: February 13, 2015)
170
Estimated Study Completion Date  ICMJE January 28, 2021
Actual Primary Completion Date January 29, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

  • Patients must have previously untreated MDS, AML, or CMML according to the WHO 2016 classification.
  • MDS patients must have Intermediate (>3 to 4.5 points), High Risk (>4.5 - 6) or Very High Risk (>6 points) disease according to the Revised International Prognostic Scoring System 2012 (IPSS-R).
  • Clinical indication for treatment with azacitidine for MDS or AML.

Exclusion criteria:

  • Patients with AML who are candidates for standard induction chemotherapy as first line treatment.
  • Patients with known active CNS leukemia.
  • Prior treatment with a smoothened inhibitor (SMOi) and/or hypomethylating agent.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Canada,   France,   Germany,   United Kingdom,   United States
Removed Location Countries Taiwan
 
Administrative Information
NCT Number  ICMJE NCT02367456
Other Study ID Numbers  ICMJE B1371012
2014-001345-24 ( EudraCT Number )
BRIGHT MDS&AML1012 ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date November 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP